SRPT Q4 2025 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$443M-32.7% YoY

Gross Profit

$2M0.5% margin

Operating Income

-$370M-83.4% margin

Net Income

-$283M-63.9% margin

EPS (Diluted)

$-3.93

QoQ Revenue Growth

+10.9%

Cash Flow

Operating Cash Flow

$131M

Free Cash Flow

$125M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$2.2B

Stockholders' Equity

$1.1B

Cash & Equivalents

$801M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$443M	$658M	-32.7%
Gross Profit	$2M	$526M	-99.6%
Operating Income	-$370M	$162M	-328.6%
Net Income	-$283M	$159M	-277.8%

Geographic Segments

UNITED STATES

$33M100%